Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174259
Title: HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Author: Mothe, Beatriz
Rosas-Umbert, Miriam
Coll, Pep
Manzardo, Christian
Puertas, Maria C.
Morón-López, Sara
Llano, Anuska
Miranda, Cristina
Cedeño, Samandhy
López, Miriam
Alarcón-Soto, Yovaninna
Gómez Melis, Gudalaupe
Langohr, Klaus
Barriocanal, Ana M.
Toro, Jessica
Ruiz, Irene
Rovira, Cristina
Carrillo, Antonio
Meulbroek, Michael
Crook, Alison
Wee, Edmund G.
Miró Meda, José M.
Clotet, Bonaventura
Valle, Marta
Martinez-Picado, Javier
Hanke, Tomás
Brander, Christian
Moltó, José
B.C.N02 Study Investigators
Keywords: VIH (Virus)
Vacunació
HIV (Viruses)
Vaccination
Issue Date: 6-May-2020
Publisher: Frontiers Media
Abstract: Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulted in increased histone acetylation, cell-associated HIV-1 RNA, and T-cell activation, which were associated with a marginally significant reduction of the viral reservoir. Vaccinations boosted robust and broad HIVconsv-specific T cells, which were strongly refocused toward conserved regions of the HIV-1 proteome. During a monitored ART interruption phase using plasma viral load over 2,000 copies/ml as a criterium for ART resumption, 23% of individuals showed sustained suppression of viremia up to 32 weeks without evidence for reseeding the viral reservoir. Results from this pilot study show that the combined kick&kill intervention was safe and suggest a role for this strategy in achieving an immune-driven durable viremic control.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00823
It is part of: Frontiers in Immunology, 2020, vol. 11, num. 823
URI: http://hdl.handle.net/2445/174259
Related resource: https://doi.org/10.3389/fimmu.2020.00823
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
701544.pdf3.43 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons